i n f l a r x

Loading

Impressum Privacy policy

Contact us

+49 3641 508 180

info@inflarx.de

Address

InflaRx N.V.

Winzerlaer Str. 2, 07745 Jena

Press Release
Home Investors Press Releases Press Release

InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum

Nov 06, 2023

Time to read 4 Minutes
  Download PDF


Back